ResearchSafe

Telmisartan (Telmisartan (ARB / Partial PPAR-gamma Agonist))

Category: Cardiovascular. Status: FDA-approved drug.

An FDA-approved angiotensin receptor blocker (ARB) for blood pressure that is a favorite in longevity circles because, unlike other ARBs, it also partially activates PPAR-gamma, giving it metabolic and mitochondrial benefits beyond blood pressure control.

How it works

Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis.

Key facts

  • Molecular weight: 514.62 Da
  • Half-life: ~24 hours
  • Bioavailability: ~42-58% oral
  • Storage: Room temperature, protect from moisture.

Dosing overview

  • Typical dose: 20-80 mg per day
  • Frequency: Once daily
  • Duration: Ongoing
  • Route: Oral tablet

Protocol notes

  • Common start is 40 mg once daily, adjusted to 20-80 mg by blood pressure response.
  • Its long half-life gives smooth 24-hour coverage from a single daily dose.
  • Longevity users favor it over other ARBs for the added PPAR-gamma metabolic effects.

Reported benefits

  • Blood pressure control
  • PPAR-gamma metabolic benefits
  • Improved insulin sensitivity
  • Vascular anti-inflammatory effects
  • Cardio- and reno-protection
  • 24-hour coverage

Possible side effects

  • Dizziness/low blood pressure
  • Hyperkalemia
  • Rare kidney function changes
  • Contraindicated in pregnancy
  • Fatigue

Research

  • Telmisartan PPAR-gamma activity (2018): Uniquely among ARBs, telmisartan partially activated PPAR-gamma, improving insulin sensitivity and lipid profiles.
  • ONTARGET cardiovascular outcomes (2008): Telmisartan was as effective as ramipril for reducing cardiovascular events with better tolerability.

Compare Telmisartan

Research and educational reference only. Not medical advice.